Gossamer Bio Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| By: | /s/ Faheem Hasnain |
| Faheem Hasnain | |
| President and Chief Executive Officer | |
| Date | March 5, 2024 |
SIGNATURES AND POWER OF ATTORNEY
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Faheem Hasnain | President, Chief Executive Officer and Chairman of the Board of Directors(principal executive officer) | March 5, 2024 |
| Faheem Hasnain | ||
| /s/ Bryan Giraudo | Chief Operating Officer and Chief Financial Officer(principal financial andaccounting officer) | March 5, 2024 |
| Bryan Giraudo | ||
| /s/ Russell Cox | Director | March 5, 2024 |
| Russell Cox | ||
| /s/ Thomas Daniel, M.D. | Director | March 5, 2024 |
| Thomas Daniel, M.D. | ||
| /s/ Renée Galá | Director | March 5, 2024 |
| Renée Galá | ||
| /s/ Sandra Milligan, M.D., J.D. | Director | March 5, 2024 |
| Sandra Milligan, M.D., J.D. | ||
| /s/ John Quisel, J.D., Ph.D. | Director | March 5, 2024 |
| John Quisel, J.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.